AK, AL, SJ, and MM wrote the initial manuscript. it out in anyone having sensory symptoms or weakness during or after a COVID-19 contamination. Its early detection and treatment can result in improved clinical outcomes. (10)Ten days after COVID-19 symptomsQuadriplegia, hypotonia, areflexia and bilateral positive Lasgue signIncreased Imeglimin protein level at 1 g/LNormal white blood cell countIntravenous immunoglobulin (2 g/kg for 5 days)Hydroxychloroquine (600 mg per day) and AzithromycineNo significant neurological improvement was seen after 1 week of treatment.Sixty years, Male Imeglimin (11)Day 20 of hospitalizationAcute weakness in lower limbs with distal distributionFoot drop on the right side.Gastroplegia, paralytic ileus, and loss of blood pressure controlOligoclonal bands seen.Increased ratio IgG/albumin in CSF (170)Normal total protein levelIntravenous immunoglobulin (0.4 g/kg/day)After 5 days, the vegetative symptomatology significantly improved, with the remission of gastroplegia and recovery of intestinal functions.Persistence of osteotendinous hyporeflexia but slight improvement in Imeglimin the right foot drop.Sixty-five years, Male (12)Two weeks after hospitalizationAcute progressive symmetric ascending quadriparesisN.AIntravenous Immunoglobulin (0.40 g/kg/day) for 5 daysN.AFifty-five years, Female (13)Day 26 of hospitalizationAcute Imeglimin progressive lower limb weaknessAverage glucose, cell count, and protein (57 mg/dL protein)The patient started on intravenous immunoglobulin (20 g IV daily for 5 days)On the third day of IVIG treatment, she designed acute respiratory distress syndrome (ARDS).Seventy-seven years, Female (14)Seven days after COVID-19 symptomsTetraplegia, areflexia, paresthesia in upper limbs, facial diplegia, dysphagia, tongue weakness, and respiratory failure.Albuminocytological dissociationTwo cycles Imeglimin of intravenous immunoglobulinPersistence of severe upper-limb weakness, dysphagia, and lower-limb paraplegia.Twenty-three years, Male (14)Ten days after COVID-19 symptomsFacial diplegia, areflexia, lower limbs paresthesia, and ataxiaAlbuminocytological dissociationProtein level: 123 mg/dlno cellsnegative PCR assay for SARS-CoV-2Intravenous immunoglobulin receivedHad improvements, including decrease in ataxia and mild decrease in facial weakness.Fifty-seven years, Male (15)Twelve days after the resolution of COVID-19 symptomsNumbness and tingling in the hands and feet.Over 10 days, the patient developed distal limb weakness and severe gait impairmentNormal cell count and normal proteinsNormal CSF/serum albumin ratioAbsence of oligoclonal bandingIntravenous immunoglobulin cycle at 0.4 g/kg/day over 5 daysSignificant improvement of the weakness in the upper limbs and the left foot but a poor benefit on the right foot and gait ataxic.Slowly improvement by physiotherapy and, after 1 month, able to walk without aid and was discharged.Seventy-six years, Male (16)Five to Seven days after COVID-19 symptomsDiarrhea, coughing, and a history of 1-week common cold.Unable to move lower limbs and not able to stand or walkHigh Protein: 76 mg/dLIntravenous immunoglobulin (20 g/day for 5 daysconcomitant anti- COVID treatmentDischarged to home with good recovery.Fifty-four years, Male (17)AfebrileAscending progression of weakness. afebrile and severe dysautonomiaNo albumino-cytological dissociation in CSFIntravenous immunoglobulin and invasive ventilationPassed awayThirty-six years, Female (17)Twelve days after COVID-19 symptomsAscending progression of weaknessAlbuminocytological dissociationIntravenous immunoglobulinDischarged with good improvement.Sixty-six years, Male (18)One month after the COVID symptomsProgressive ascending weaknessHigh protein 0.6 g/L (0.15C0.45 g/L)High glucose 3.97 mmol/L (2.2C3.9 mmol/L) Normal cell countsStarted on intravenous immunoglobulin at (0.4 g/kg IV) once daily for 5 daysImproved clinically, with power 4/5 in the upper extremities and 3/5 in of the lower extremities. The patient was discharged.Fifty-five year, Female (19)Twenty-six day after hospitalizationDecreased muscle strength in lower limbsGlucose: 78 mg/dLProtein: 48,4 mg/dL (normal value: 50 mg/dL),No white blood cells (WBCs).Intravenous immunoglobulinPassed away due to acute respiratory distress syndrome (ARDS) before the medication could start its effect.Sixty-one year, Male (20)A month after COVID-19 symptomsFlaccidity in all of the upper and lower limb musclesN.AStarted on intravenous immunoglobulin (400 mg/kg body weight daily, for 5 days)Significant clinical alleviation of symptoms with improvement in Lecirelin (Dalmarelin) Acetate respiratory functions, oxygen saturation, and return of muscle power, recovering to 4/5 power in the upper and reduce limbs on both sides. Open in.